Market forces rained on the parade of Silence Therapeutics plc (LON:SLN) shareholders today, when the analysts downgraded their forecasts for this year. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon.

Following the downgrade, the most recent consensus for Silence Therapeutics from its two analysts is for revenues of UK£13m in 2020 which, if met, would be a huge increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 45% to UK£0.14. Yet prior to the latest estimates, the analysts had been forecasting revenues of UK£21m and losses of UK£0.041 per share in 2020. Ergo, there’s been a clear change in sentiment,